In the full year 2025, AbbVie delivered revenue of $58.3 billion, outpacing the broader S&P 500 pharmaceutical index by 7 percentage points. Despite the 2023 loss of global patent exclusivity on its flagship immunology drug, Humira, the company’s diversified portfolio—anchored by growth therapies in aesthetics (up 18%) and oncology (up 12%)—helped offset a 22% decline in Humira sales. Management cited resilient demand for newly launched migraine treatment Ubrelvy and the immunology asset Skyrizi, which generated combined revenues of $11.2 billion, as key drivers of outperformance. AbbVie’s adjusted EBITDA margin expanded by 120 basis points to 54.7%, underscoring successful cost synergies realized in its acquisition of Allergan.

Analysts project fourth-quarter core EPS growth of 4% year-over-year, with consensus revenues at $14.6 billion—roughly flat sequentially as seasonal revenues from aesthetics (Botox and filler products) typically decelerate. Of the 26 firms covering AbbVie, 15 expect an earnings beat, while 11 anticipate a modest miss driven by operational headwinds in the immunology franchise. Investors will focus on guidance for 2026, where management has signaled mid-single-digit top-line growth and free cash flow north of $16 billion, funded primarily by mature products and a pipeline featuring five phase-III studies.

In the two weeks leading into the earnings release, AbbVie’s one-month implied volatility rose by 14%, outpacing the sector average increase of 8%. Call open interest for January-expiry contracts increased by approximately 22%, while put open interest remained steady, pushing the put-call ratio down to 0.85 from 1.03. This shift indicates that traders are positioning for a potential upside move or muted downside surprises. Notably, the skew between 25-delta calls and puts has narrowed to 2.5 volatility points, the tightest level seen in three quarters, suggesting elevated confidence in limited share-price swings around the report.